Abstract Submission Rules & Guidelines
All 2019 Canadian Hypertension Congress sessions will be conducted in English. All abstracts must be submitted in English.
Abstract Deadline: Abstracts must be received electronically through the website no later than June 30th, 2019 at 11:59 p.m. (EST). Paper submissions or faxed abstracts will not be accepted.
- There is no fee for submitting abstracts to the 2019 Canadian Hypertension Congress.
- The submitting Trainee and Supervisor must be current members of Hypertension Canada in order for the Trainee to receive a Travel Award. Please see Trainee Travel Award Guidelines for award details.
- Misrepresentation of affiliations, trainee status for the Student Presentation Awards, or other information will result in disqualification or withdrawal of the abstract.
- All presenting authors must register for the Congress and are responsible for their own registration, transportation and accommodation costs.
- Submission of an abstract constitutes a commitment by the author(s) to present their work at the Congress.
- Submission of an abstract constitutes a commitment by the author(s) as to the integrity of the data and that they agree with the submission and its intended uses within the Congress.
- Incomplete submissions will not be accepted.
- Within 5 business days of submission, the submitter will receive a confirmation email and a copy of the abstract (in a Word document) for review and edits if necessary. No editing of any abstracts is done by Hypertension Canada. The submitter is responsible to edit the Word document and reply to the confirmation email; otherwise the abstract will proceed exactly as submitted.
- If you are submitting an abstract to multiple meetings (including the CCC, AHA, ACC and ESC) please ensure that you are fully aware of their submission guidelines and regulations.
General Formatting Guidelines:
- Use standard abbreviations (LV, RBC, mEQ). Place unusual abbreviations in parenthesis after the full word, the first time it appears. Keep abbreviated terms to a minimum.
- Use numerals to indicate numbers except to begin sentences.
- Use non-proprietary (generic) names for drugs.
- Symbols can be embedded in the abstract body. Hypertension Canada is not responsible for any symbols, graphics, fonts or special characters which do not appear or are lost in translation due to software or hardware incompatibilities with the file submitted. Abstract
The limit for an abstract submission is 300 words.
- Do not re-enter the abstract title or the authors’ names/institutions in the body of the abstract.
- The body of the abstract should include the following section titles in your text.
- Learning Objectives/Initiatives: Include one key point that the authors wish to communicate to the audience.
- Background: A brief statement of the purpose of the study.
- Method/Results: A statement of the method(s) of investigation and a summary of the results presented in sufficient detail to support conclusions. Images will not be accepted.
- Conclusion: A brief statement of results reached. (Note that it is unacceptable to state “the results will be discussed”.)
- Individual submitters are limited to a maximum of two abstract submissions.
- Request oral or poster presentation in the Presentation Preference box of the Abstract Form. Selecting oral or poster preferred will neither prejudice acceptance nor guarantee oral or poster presentation, as abstracts must be arranged to fit into a thematic group for presentation. However, the Congress Scientific Program Committee will make every effort to accommodate your presentation request. If you select “Poster” only and your abstract is accepted, this request will be granted.
- If authors’ names appear on more than one abstract, their names must appear identically as that author would enter it. This consistency streamlines the process of proper indexing in the program. Whenever possible, do not list authors with initials only.
- Your abstract, if selected, will be published in print and/or electronic version as submitted. Please note that the entire Abstract (Learning Objectives/Initiatives, Background, Method/Results, and Conclusion) will be available for viewing in the program. No change in abstract title, content, and names or order of authors will be accepted after submission deadline.
- A submitter should not “split” data to create several abstracts from one. If splitting is judged to have occurred, scores of related abstracts will be reduced.
- Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals may be disqualified.
Grading and Selection of Abstracts
Abstract grading is blind and conducted by a group of experts within a relevant field. The Review Committee is responsible for grouping the abstracts appropriately for their particular specialty or association. Abstracts are selected on the basis of scientific merit.
Notice of Status of Abstract
All abstracts submitted must comply with these guidelines to be considered for acceptance. Notification of acceptance or rejection of abstracts will be emailed by July 22nd, 2019. Guidelines for oral or poster presentations will be provided to authors of accepted abstracts.
Send questions or requests for assistance via email to: [email protected]